• Helpful online tools and downloadable, printable materials are available to you here. And in our FAQs, you’ll find answers to many frequently asked questions.
    • Test Your Gout Knowledge

      Test Your Gout Knowledge

      How much do you know about gout? Take this interesting and informative gout quiz to find out.

      TAKE QUIZ
    • Gout Friendly Diet Cheat Sheet

      Gout Friendly Diet Cheat Sheet

      Discover the benefits of a gout-friendly diet that may reduce your risk of future flares.

      INFOGRAPHIC
    • Sidestep these Foods to Avoid Gout Flare-ups

      Sidestep these Foods to Avoid Gout Flare-ups

      See this checklist of foods your doctor may recommend that you limit or avoid.

      INFOGRAPHIC
    • Gout Flare Questionnaire

      Gout Flare Questionnaire

      Use this printable form to talk with your doctor about your gout flares.

      DOCTOR VISIT FORM
    • Get Your Mitigare<sup>®</sup> Prescription Filled

      Get Your Mitigare® Prescription Filled

      Find out about convenient options for filling your Mitigare® or Generic Colchicine Capsules prescription.

      FIND A PHARMACY
    • Mitigare<sup>®</sup> Medguide

      Mitigare® Medguide

      Download a copy of our Medication Guide for important information.

      Download
    • Mitigare<sup>®</sup> Prescribing Information

      Mitigare® Prescribing Information

      Download a copy of the Mitigare® Prescribing Information PDF.

      Download

Go to All Resources

 

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.